Please note: The information displayed on this page might be outdated.
Cellestia Biotech AG: Cellestia develops anti-cancer drugs designed to promote efficiency in oncology therapy. The company's drugs offer a mode of action for the treatment of NOTCH dependent leukemias, lymphomas and solid tumors through oral medication, enabling patients to get efficient treatment and ensure a fast recovery.

Cellestia is completing a Phase l first-in-man clinical trial with CB-103 treating cancer patients in the EU. US FDA approved the IND in Q1 2019. Daily treatment with CB-103 has been so far very well tolerated, confirming the excellent safety and favorable pharmacokinetic profile.
Sector/industry:
Healthcare
Characteristics:
Based in...
Europe
Disease Space
Oncology
Listing
Private
Website:
Profiles:
Address:
Hochberger Strasse 60 C
Basel, Vaud 4057
Switzerland

Company Participants at Summer 2020 NYC Private Company Showcase

  • Gaudenz von Capeller, Chief Financial Officer

Send Message to Request Information

Log in to download presentation, request a 1x1 meeting, view additional roadshows, and more.

Upcoming Company Event Participation

Summer 2020 NYC Private Company Showcase

New York, NY, August 10, 2020